



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 13/00, 15/00, A61K 37/02 A61K 37/64, C12P 21/02 C12N 15/24, 15/70, C07H 15/12		A1	(11) International Publication Number: <b>WO 93/05071</b>		
			(43) International Publication Date: 18 March 1993 (18.03.93)		
(21) International Application Number: PCT/US91/06595		(81) Designated States: AU, BR, CA, FI, HU, JP, KR, NO, SU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE).			
(22) International Filing Date: 12 September 1991 (12.09.91)					
(30) Priority data: 750,644 30 August 1991 (30.08.91) US		Published <i>With international search report.</i>			
(71) Applicant: IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US).					
(72) Inventors: BLACK, Roy, A. ; 8062 30th Avenue N.E., Seattle, WA 98115 (US). SLEATH, Paul, R. ; 836 West Armour Street, Seattle, WA 98119 (US). KRONHEIM, Shirley, R. ; 11526 36th Northeast, Seattle, WA 98125 (US).					
(74) Agents: KATZ, Martin, L.; Dressler, Goldsmith, Shore, Sutker & Milnamow, Two Prudential Plaza, Suite 4700, 180 North Stetson Avenue, Chicago, IL 60601 (US) et al.					

(54) Title: INTERLEUKIN 1 $\beta$  PROTEASE AND INTERLEUKIN 1 $\beta$  PROTEASE INHIBITORS

## (57) Abstract

There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1 $\beta$  and for a substrate comprising: R<sub>1</sub>-Asp-R<sub>2</sub>-R<sub>3</sub> wherein R<sub>1</sub> and R<sub>3</sub> are independently any D or L isomer amino acid, R<sub>2</sub> is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R<sub>2</sub>. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1 $\beta$  protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

INTERLEUKIN 1 $\beta$  PROTEASE  
AND INTERLEUKIN 1 $\beta$  PROTEASE INHIBITORS

5

TECHNICAL FIELD OF THE INVENTION

This invention relates to an interleukin 1 $\beta$  protease enzyme (IL-1 $\beta$  pro) having biological activity to cleave inactive precursor interleukin-1 $\beta$  (IL-1 $\beta$ ) polypeptides into active mature IL-1 $\beta$  polypeptides. More specifically, the invention provides an isolated IL-1 $\beta$  pro polypeptide and derivatives thereof that are capable of cleaving a particular amino acid sequence, including the amino acid sequence at the N-terminus of human IL-1 $\beta$ . The present invention further provides a group of compounds that can inhibit IL-1 $\beta$  pro activity and thereby function as IL-1 antagonists.

SUMMARY OF THE INVENTION

The present invention is directed to an isolated polypeptide having proteolytic activity for a specific protease cleavage site, wherein the protease activity is specific for a substrate peptide having an amino acid sequence comprising:

25



wherein R<sub>1</sub> and R<sub>3</sub> are independently any D or L isomer amino acid, R<sub>2</sub> is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R<sub>2</sub>. Preferably, the substrate peptide is at least eight amino acids in length. The isolated polypeptide is called the interleukin 1 $\beta$  protease (IL-1 $\beta$  pro) because it cleaves precursor IL-1 $\beta$  polypeptide to yield mature IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues.

The present invention further comprises a recombinant expression vector comprising an isolated DNA sequence as described herein and a host cell which comprises the recombinant expression vector.

5 The present invention also provides substituted peptide IL-1 $\beta$  inhibitor compounds comprising an amino acid sequence of from 1 to about 5 amino acids, having an N-terminal protecting group and a C-terminal Asp residue connected to an electronegative leaving group. Preferably, the amino acid sequence corresponds to at least a portion of the amino acid sequence Ala-  
10 Tyr-Val-His-Asp.

The inhibitor compounds of the present invention have the formula:

15  $Z-Q_2\text{-Asp-}Q_1$   
Where  $Z$  is an N-terminal protecting group;  $Q_2$  is 0 to 4 amino acids such that the sequence  $Q_2\text{-Asp}$  corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of sequence listing I.D. No. 3; and  
20  $Q_1$  comprises an electronegative leaving group.  $Z$  is preferably  $C_1\text{-}C_6$  alkylketone, benzyl, acetyl, alkoxy carbonyl, benzloxy carbonyl or  $C_1\text{-}C_6$  alkyl carbonyl. More preferably,  $Z$  is t-butoxycarbonyl (t-Boc), acetyl carbonyl or benzylloxycarbonyl (Cbz).

25  $Q_1$  is preferably  $C_1\text{-}C_3$  alkyl, an aldehyde diazomethyl ketone or halomethyl ketone. More preferably,  $Q_1$  is an aldehyde or fluoromethyl ketone.

The present invention further provides reversible and irreversible IL-1 $\beta$  pro inhibitors.  
30 Irreversible inhibitors are inhibitor compounds comprising an amino acid sequence of from 1 to about 5 amino acids having an N-terminal protecting group and a C-terminal Asp residue connected to a diazomethyl ketone or a halomethyl ketone, wherein the amino acid sequence corresponds to at least a portion of the sequence Ala-  
35

- 3 -

Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

Reversible IL-1 $\beta$  inhibitors are compounds comprising an amino acid sequence of from 1 to about 5 amino acids having an N-terminal protecting group and a C-terminal Asp residue connected to an aldehyde moiety, wherein the amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

5 The present invention also provides a method of inhibiting the physiological actions of interleukin 1 $\beta$  in a mammal in need of such treatment, comprising administering to said mammal an effective amount of the inhibitor compounds of the present invention.

10 The present invention still further provides a pharmaceutical composition comprising a physiologically acceptable carrier and an inhibitor compound of the present invention.

15 The present invention still further provides a method of treating inflammation associated with autoimmune disease in a mammal in need of such treatment comprising administering to said mammal an effective anti-inflammatory amount of an inhibitor compound of the present invention.

20 The present invention further comprises a method for treating arthritis, a method for treating an autoimmune disease in a susceptible individual, a method for improving wound healing, and a method for reducing the detrimental side effects of radiation treatment. All of the methods comprise administering a 25 therapeutically effective amount of an isolated IL-1 $\beta$  protease or a biologically active derivative thereof in a suitable pharmaceutical carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings forming a portion of this disclosure:

5 Figure 1 shows the DNA (Seq. I.D. No. 1) and corresponding amino acid sequence (Seq. I.D. No. 2) for a polypeptide having IL-1 $\beta$  pro biological activity and corresponding to human mature IL-1 $\beta$  pro or a biologically active fragment thereof.

10 Figure 2 is the amino acid sequence of preIL-1 $\beta$  (Seq. I.D. No. 3), as published by March et al., Nature (London), 315(6021):641-647 (1985). The amino acid residues are numbered (underneath the sequence) beginning with the initiator methionine.

15 Figure 3 shows a Western Blot analysis of products generated by IL-1 $\beta$  pro in the presence and absence of the IL-1 $\beta$  pro inhibitor Boc-Asp-CH<sub>2</sub>F. Products were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with an antibody raised against the COOH terminus of mature IL-1 $\beta$ . Lane 3. preIL-1 $\beta$  incubated with 25  $\mu$ M of inhibitor; lane 4. preIL-1 $\beta$  incubated with 10  $\mu$ M of inhibitor; lane 5. preIL-1 $\beta$  incubated with 5  $\mu$ M inhibitor, lane 6. preIL-1 $\beta$  incubated with 1  $\mu$ M inhibitor.

DETAILED DESCRIPTION OF THE INVENTIONI. Interleukin 1 $\beta$  Protease

25 Utilizing polymerase chain reaction (PCR) procedures and other techniques, we have isolated, purified, characterized, and expressed a mammalian IL-1 $\beta$  pro polypeptide and active fragments thereof.

30 The availability of abundant quantities of a recombinant IL-1 $\beta$  pro enzyme has further allowed us to find inhibitor compounds capable of inhibiting IL-1 $\beta$  pro activity and thereby function as IL-1 antagonists. Further, use of IL-1 $\beta$  pro has IL-1 agonist activity.

- 8 -

Thus, the invention relates to mammalian IL-1 $\beta$  pro polypeptides, derivatives, analogs and allelic variants thereof having proteolytic activity for a substrate peptide having an amino acid sequence comprising:

5

$R_1 - Asp - R_2 - R_3$

wherein  $R_1$  and  $R_3$  are independently any D or L isomer amino acid,  $R_2$  is Ala or Gly, and wherein the specific protease cleavage site is between Asp and  $R_2$ .

10

Preferably, the substrate peptide is at least eight amino acids in length. Most preferably,  $R_2$  is Gly.

15

Mammalian IL-1 $\beta$  pro is preferably a human IL-1 $\beta$  pro and has substrate specificity for a substrate peptide having the amino acid sequence described herein. Preferably, the human IL-1 $\beta$  pro polypeptide or derivative thereof is a polypeptide having biological activity that cleaves human precursor IL-1 $\beta$  polypeptide to yield human mature IL-1 $\beta$  polypeptide.

20

IL-1 $\beta$  pro is further characterized by the cDNA (Seq. I.D. No. 1) and amino acid sequence (Seq. I.D. No. 2) in Figure 1. Full length (precursor) IL-1 $\beta$  pro comprises 404 amino acids. Purified IL-1 $\beta$  pro begins with the Asn-Pro-Ala-Met-Pro sequence beginning with amino acid 120. Based upon a molecular weight analysis, the approximate C-terminus of mature IL-1 $\beta$  pro is about amino acid 297. However, the molecular weight determination indicates that the C-terminus of the mature enzyme is from about amino acid 278 to about amino acid 315. The present invention comprises an isolated IL-1 $\beta$  pro polypeptide or a derivative, analog, or allelic variant thereof displaying biological activity to proteolytically cleave a human precursor IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. For the purposes of this application, the term "IL-1 $\beta$  pro" shall encompass the amino acid sequence shown in Figure 1, plus all allelic

25

30

35

variants, derivatives, analogs and fragments of this sequence that display IL-1 $\beta$  pro biological activity.

IL-1 $\beta$  pro biological activity is determined, for example, by assaying for IL-1 activity with a precursor IL-1 $\beta$  polypeptide. Precursor IL-1 $\beta$  is inactive, while mature IL-1 $\beta$  is an active IL-1 polypeptide. A method for measuring IL-1 $\beta$  pro activity is described in Black et al. II. Briefly, this method provides approximately five microliters of precursor IL-1 $\beta$  (pre IL-1 $\beta$ ) (10-50  $\mu$ g/ml prepared as described in Black et al. I) incubated with 10  $\mu$ l of IL-1 $\beta$  pro polypeptide or another substance suspected of having IL-1 $\beta$  pro biological activity. The incubation proceeds for approximately one hour at approximately 37°C and is terminated by the addition of 15  $\mu$ l of 2 X SDS sample buffer followed by boiling for five minutes. The boiled sample is electrophoresed on a SDES-polyacrylamide gel and placed onto a Western blot using an IL-1 $\beta$  C-terminal-specific monoclonal antibody, such as 16F5 described in Black et al. I.

Figure 1 also shows a nucleotide sequence encoding a 404 amino acid sequence having IL-1 $\beta$  pro biological activity. The present invention further comprises an isolated DNA sequence encoding IL-1 $\beta$  pro or a derivative, analog or allelic variant thereof displaying biological activity to proteolytically cleave a human precursor IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. The isolated DNA sequence is selected from the group consisting of the nucleotide sequences in Figure 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962, DNA sequences which detectably hybridize to the Figure 1 sequence from

5 nucleotide 1 to nucleotide 1232 and encode a polypeptide displaying biological activity to proteolytically cleave a human precursor IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues, and DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 $\beta$  pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

10 Inventive DNA sequences that detectably hybridize to the Figure 1 nucleotide sequence from nucleotide 1 to nucleotide 856, hybridize under conditions of high or severe stringency. Severe or high stringency conditions comprise, for example, overnight hybridization at about 68°C in a 6 X SSC solution followed by washing at about 68°C in a 0.6 X SSC 15 solution.

20 Antisense oligonucleotides can be synthesized (by conventional phosphodiester techniques such as by Synthecell, Rockville, MD) that are complementary to unique regions of at least 18 bases at the initiation codon (TACCGGCTGTTCCAGGAC, Seq. I.D. No. 4) or (TACCTATTCTGGGCTCGA, Seq. I.D. No. 5) complementary to bases 18-36 and 168 to 196, respectively in Figure 1, at the N-terminus of mature IL-1 $\beta$  pro (TTGGTCGATAACGGGTGT, Seq. I.D. No. 6) complementary to bases 374 to 392 in Figure 1, at the approximate C terminus after protease 25 cleavage (CACACACCAAATTCTA, Seq. I.D. No. 7) complementary to bases 890 to 908 in Figure 1, or at a region immediately 5' to the termination codon (ATGGAGAAGGGTCCTGTA, Seq. I.D. No. 8) complementary to bases 1205 to 1229 in Figure 1.

30 The primary amino acid structure of IL-1 $\beta$  pro or its active fragment thereof may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids; phosphate, acetyl groups and the like, or by creating 35

amino acid sequence mutants or derivatives. Covalent derivatives of IL-1 $\beta$  pro are prepared by linking particular functional groups to IL-1 $\beta$  pro amino acid side chains or at the N-terminus or C-terminus of the 5 IL-1 $\beta$  pro polypeptide.

Other derivatives of IL-1 $\beta$  pro within the scope of this invention include covalent or aggregative conjugates of IL-1 $\beta$  pro or its fragments with other proteins or polypeptides, such as by synthesis in 10 recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated polypeptide may be a signal (or leader) polypeptide sequence at the N-terminal region of IL-1 $\beta$  pro polypeptide which co-translationally or post-translationally directs transfer of the IL-1 $\beta$  15 pro polypeptide from its site of synthesis to a site inside or outside of the cell membrane or wall (e.g., the yeast  $\alpha$ -factor leader). IL-1 $\beta$  pro polypeptide fusions can comprise polypeptides added to facilitate purification and identification of IL-1 $\beta$  pro (e.g., 20 poly-His). Further, the amino acid sequence of IL-1 $\beta$  pro can be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (Hopp et al. BioTechnology 6:1204 (1988)), which is a highly antigenic sequence and provides an 25 epitope reversibly bound by a specific monoclonal antibody to enable rapid assay and facile purification of the expressed recombinant polypeptide. This specific leader sequence is cleaved by bovine mucosal enterokinase at the residue immediately following the 30 Asp-Lys pairing. Moreover, fusion polypeptides having this leader sequence at its N-terminal may be resistant to degradation in E. coli host cells.

The present invention further includes IL-1 $\beta$  pro polypeptides with or without associated native-pattern glycosylation. IL-1 $\beta$ , pro expressed in yeast or 35 mammalian expression systems (e.g., COS-7 cells) may be

- 9 -

similar or significantly different in molecular weight and glycosylation pattern than the native human IL-1 $\beta$  pro polypeptide. This depends upon the choice of expression system. Expression of IL-1 $\beta$  pro polypeptides in bacterial expression systems, such as *E. coli*, provides non-glycosylated molecules.

Functional mutant analogs of human IL-1 $\beta$  pro can be synthesized, for example, with inactivated N-glycosylation sites by oligonucleotide synthesis and ligation or by site specific mutagenesis techniques. The IL-1 $\beta$  pro derivatives can be expressed in homogeneous, reduced carbohydrate form using yeast expression systems. N-glycosylation sites in eukaryotic polypeptides are characterized by an amino acid triplet Asn- $\Phi$ - $\Omega$  where  $\Phi$  is any amino acid except Pro and  $\Omega$  is Ser or Thr. In this sequence, carbohydrate residues are covalently attached at the Asn side chain.

IL-1 $\beta$  pro analogs or derivatives may also be obtained by mutations of the IL-1 $\beta$  pro DNA sequence. An IL-1 $\beta$  pro mutant derivative, as referred to herein, is a polypeptide substantially homologous to IL-1 $\beta$  pro but which has an amino acid sequence different from native IL-1 $\beta$  pro because of a deletion, insertion or substitution.

IL-1 $\beta$  pro is expressed from a mammalian gene, presumably encoded by one or more multi-exon genes. The present invention further includes alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share regions of identity or similarity with the cDNA's disclosed herein.

Bioequivalent analogs of IL-1 $\beta$  pro polypeptides (defined as polypeptides having IL-1 $\beta$  pro biological activity) can be constructed, for example, by making various substitutions of amino acid residues or

5 sequences, or by deleting terminal or internal residues or sequences not needed for biological activity. For example, Cys residues can be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present.

10 Generally, substitutions are made conservatively by substituting an amino acid having physiochemical characteristics resembling those of the replaced residue. Further substitutions may be outside of the "core" sequence needed for IL-1 $\beta$  pro biological 15 activity. Subunits of IL-1 $\beta$  pro may be constructed by deleting terminal or internal residues or sequences. The resulting polypeptide should have IL-1 $\beta$  pro biological activity as defined herein.

20 The terms "IL-1 $\beta$  pro", "human IL-1 $\beta$  protease" include, but are not limited to, analogs or subunits of IL-1 $\beta$  pro which are substantially similar to human IL-1 $\beta$  pro and/or which exhibit the substrate-specific proteolytic biological activity associated with IL-1 $\beta$  pro as described herein.

25 The term "substantially similar", when used to describe amino acid sequences, means that a particular sequence may vary from a disclosed reference sequence by one or more substitutions, deletions, or additions. However, the net effect is the same protease biological 30 activity characteristic of the reference human IL-1 $\beta$  pro polypeptide. For example, a derivative can have a truncated sequence comprising a "core region" or a sequence of amino acids necessary for the specific protease biological activity characteristic of IL-1 $\beta$  pro. Substantially similar IL-1 $\beta$  pro derivatives will 35

- 11 -

be greater than about 30% similar to the corresponding sequence of human IL-1 $\beta$  pro and have IL-1 $\beta$  pr biological activity. Polypeptides having amino acid sequences of lesser degrees of similarity but comparable 5 biological activity (including substrate specificity) are considered to be equivalents. More preferably, the derivative polypeptides will have greater than 80% amino acid sequence homology to human IL-1 $\beta$  pro polypeptide.

Percent similarity may be determined, for 10 example, by comparing sequence information using a GAP computer program, version 6.0, available from University of Wisconsin Genetics Computer Group. The GAP program uses the alignment method of Needleman and Wunsch (J. Mol. Biol., 48:443 (1970)), as revised by Smith and 15 Waterman [Adv. Appl. Math., 2:482 (1981)]. Briefly, the GAP program defines similarity as the number of aligned symbols which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program 20 include: (1) a weighted comparison matrix for amino acids [See, Schwartz and Dayhoff, eds. Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-58 (1979)]; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol 25 in each gap; and (3) no penalty for end gaps.

"Biologically active", as used herein, refers to IL-1 $\beta$  pro biological activity to cleave a particular amino acid sequence at the peptide bond between an Asp residue and an Ala or Gly residue.

30 "Recombinant", as used herein, means that a polypeptide is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a 35 polypeptide produced in a microbial expression system

which is substantially free of native endogenous substances. Polypeptides expressed in most bacterial expression systems (e.g., *E. coli*) will be free of glycan. Polypeptides expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells.

The IL-1 $\beta$  pro protease has a highly restricted substrate specificity. Human precursor IL-1 $\beta$  polypeptide has an amino acid sequence His-Asp-Ala-Pro for residues 115-118. Human IL-1 $\beta$  pro cleaves this sequence between residues 116 and 117 (Asp-Ala) to form human mature IL-1 $\beta$  polypeptide. Changing Asp-116 to Ala in a human precursor IL-1 $\beta$  polypeptide by site-directed mutagenesis prevented cleavage of the mutant IL-1 $\beta$  polypeptide derivative.

Isolated human IL-1 $\beta$  pro was able to cleave at its specific substrate site even when the tertiary structure of the substrate precursor IL-1 $\beta$  polypeptide was altered by denaturing the substrate polypeptide in boiling water. Precursor human IL-1 $\beta$  was denatured by boiling a solution of precursor IL-1 $\beta$  for fifteen minutes. Denaturation had little effect on the ability of human IL-1 $\beta$  pro to be able to cleave human precursor IL-1 $\beta$  into mature IL-1 $\beta$ . Thus, the tertiary structure of the substrate polypeptide does not significantly contribute to the reaction with the enzyme IL-1 $\beta$  pro.

IL-1 $\beta$  pro biological activity was determined by a protease assay. As the IL-1 $\beta$  pro enzyme is salt sensitive, samples having a salt concentration greater than 50 mM were initially desalting. Samples can be desalting, for example, by applying 100  $\mu$ l of sample to a pre-spun 1 ml Biogel P-6DG (Bio-Rad) column, which was equilibrated in 10 mM Tris-HCl, 5 mM dithiothreitol, pH 8.1, and centrifuging for 5 minutes at 1876 X g. The assay was conducted by incubating a mixture of five  $\mu$ l

(30 ng) of purified human IL-1 $\beta$  precursor and 10  $\mu$ l of the sample to be tested for IL-1 $\beta$  pro tease biological activity for 60 minutes at 37°C. A control sample was similarly incubated to check for endogenous IL-1. The 5 control sample mixture contained 5  $\mu$ l of 10mM Tris-HCl, pH 8.1 and 5 mM dithiothreitol instead of IL-1 $\beta$  precursor. The control sample incubations were terminated by addition of SDS (sodium dodecyl sulfate) in sample buffer followed by five minutes of boiling.

10 All incubated assay mixtures were electrophoresed on 0.75 mm-thick SDS, 14% polyacrylamide slab gels, using a discontinuous system, such as the one described in Laemmli, Nature, 277:680 (1970). Western blots were performed following electrophoresis by 15 transferring the proteins onto nitrocellulose (Sartorius) and probing using an 20  $\mu$ g/ml solution of purified IL-1 $\beta$  COOH-terminal-specific monoclonal antibody (i.e., 16F5). The blot was developed using Horseradish Peroxidase Color Developing Reagent (Bio 20 Rad). One hundred ng of purified mature IL-1 $\beta$  was used as a control 17,500 dalton marker on the Western blot.

Human IL-1 $\beta$  pro enzyme was obtained and purified from THP-1 cells obtainable from the American Type Culture Collection (ATCC). Approximately 120 25 liters of cells were cultured and then stimulated for 16 hours with liposaccharide, hydroxyurea and silica as described in Matsushima, Biochemistry, 25:3424 (1986). The cells were harvested by centrifugation, washed in Hanks balanced salt solution, and then recentrifuged. 30 The cells were resuspended in 10 mM Tris-HCl, 5mM dithiothreitol, pH 8.1 at a density of  $10^8$ /ml. The suspended cells were frozen and thawed three times and the lysates stored at -80°C until further use. Prior to purification, the lysates were thawed and then 35 centrifuged for 20 minutes at 47,800 X g at 4°C. The

supernatant was taken for further purification. The freeze-thawing procedure repeated four times released over 50% of the IL-1 $\beta$  pro activity into the supernatant. Additional freeze-thaws did not increase the yield of soluble material.

5 The human IL-1 $\beta$  pro polypeptide was purified in a six-step process described below. All the chromatography steps were performed at 4°C using a Pharmacia FPLC System. DEAE-Sephadex, Hydroxyapatite and Blue Agarose gels were pretreated with 0.1% Triton-X-100 and 10% bovine calf serum to prevent non-specific absorption of proteins to the gels. Further, the Blue Agarose column was washed with 8M urea to remove any noncovalently absorbed dye.

10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000

- 15 -

2. The pooled active fractions from the DEAE column were diluted in 50 mM potassium phosphate buffer, 5 mM dithiothreitol, pH 7.0 ("buffer B"). A 14 x 3 cm column of hydroxyapatite (HA Ultrogel, IBF Biotechnics) was equilibrated with buffer B. The diluted fractions were applied to the equilibrated hydroxyapatite column at a flow rate of 60 ml/hour. The column was washed with 2 column volumes of buffer B and then eluted with a linear gradient (4 column volumes) ranging from 50-200 mM potassium phosphate. Fractions were collected as 10 ml volumes, analyzed for IL-1 $\beta$  pro activity, and stored for further purification. IL-1 $\beta$  pro eluted between 0.085 and 0.113 M potassium phosphate. Forty percent of the contaminating polypeptides eluted before the protease and 40% eluted later than the protease. Further, endogenous mature IL-1 $\beta$  eluted between 0.05 and 0.08 M potassium phosphate.

3. A 20 x 1.6 cm Blue Agarose column (Gibco-BRL) was equilibrated with buffer A. Fractions from the hydroxyapatite column with activity were diluted 1:3 in buffer A to reduce ionic strength to 30mM. This was necessary in order to allow IL-1 $\beta$  pro to bind to the column. Diluted fractions were applied to the Blue Agarose column at a 30 ml/hour rate. The column was washed with three column volumes of buffer A. The proteins were eluted with five column volumes of a linear gradient ranging from 0.1 to 1 M NaCl in buffer A. Ten ml fractions were collected, analyzed for IL-1 $\beta$  pro activity and stored for further purification. IL-1 $\beta$  pro was eluted with 0.5 to 0.68 M NaCl. Eighty percent of the contaminating proteins were removed in this step, with 20% eluting earlier and the remaining 60% remaining bound to the column.

4. A 95 x 2.5 cm Sephadex G-75 column (Pharmacia Fine Chemicals) was equilibrated in buffer A

-16-

and initially calibrated with ferritin (MW 400,000), ovalbumin (MW 43,000), soybean trypsin inhibitor (MW 20,000) and DNP-aspartic acid (MW 300). The Blue Agarose column fractions containing protease activity 5 were pooled and concentrated on a Centriprep-10 concentrator (Amicon) to a volume of approximately 2 ml and then applied to the Sephadex G-75 column. Proteins were eluted with buffer A at a flow rate of 20 ml/hr. Four ml fractions were collected and the fractions 10 containing protease activity were pooled for further purification. IL-1 $\beta$  pro activity was eluted with between 196 and 220 ml. This position is identical to the elution position of soybean trypsin inhibitor, which suggests that human IL-1 $\beta$  pro has a molecular weight of 15 about 20,000 daltons. This step removed over 90% of the contaminating proteins from the preparation. Thus, through the Sephadex step, more than 99.8% of the starting protein contaminants have been separated from 20 IL-1 $\beta$  pro. However, PAGE (polyacrylamide gel electrophoresis) analysis of the fractions still revealed several protein bands that did not correlate with IL-1 $\beta$  pro biological activity.

5. Fractions from the Sephadex column which contained protease activity were pooled and the pool was 25 concentrated on pretreated Centriprep 10 Concentrators to a 500  $\mu$ l volume. Since protein concentration of the Sephadex pool was low (<30  $\mu$ g/ml), pretreatment of the centripreps with bovine serum albumin reduced loss of IL-1 $\beta$  pro activity during concentration. Extensive 30 washing of the treated centripreps prior to use prevented contamination of samples with albumin. Pretreatment was accomplished by centrifuging 15 ml of 1% bovine serum albumin (BSA) in centripreps for 30 minutes, decanting the remaining solution, and washing 35 with 10 mM Tris-HCl. A Mono P5/20 FPLC chromatofocusing

c column (Pharmacia Fine Chemicals) was equilibrated with 25 mM Tris-acetate and 5 mM dithiothreitol, pH 8.3 buffer. The concentrated solution was mixed (1:1 v/v) with 500  $\mu$ l of 25 mM Tris-acetate and 5 mM dithiothreitol, pH 8.3 and applied to the Mono P5/20 FPLC column. Proteins were eluted with Polybuffer 96:Polybuffer 74 (3:7) pH 5.0 (Pharmacia) at a 15 ml/hour flow rate. One ml fractions were collected and analyzed for pH and biological protease activity. This chromatofocusing step increased the purity of IL-1 $\beta$  pro a further 100 fold and allowed for the visualization of a single protein band that correlated with IL-1 $\beta$  pro biological activity. IL-1 $\beta$  pro was eluted off the chromatofocusing column between pH 6.95 and 6.70. The fractions were concentrated on BSA-pretreated Centricon 10 Concentrators (Amicon) from 1  $\mu$ l to 50  $\mu$ l.

6. The fractions were subjected to electrophoresis on a polyacrylamide gel (PAGE), followed by electroblotting onto polyvinyl difluoride membrane paper (PVDF, Millipore Immobilin-P $^{\oplus}$ ) at 300 mA for 30 minutes. The PVDF membrane was stained with Coomassie Blue. There were five major bands with molecular weights of approximately 45,000, 43,000, 36,000, 22,000 and 18,000 daltons. The 22,000 dalton band correlated with IL-1 $\beta$  pro activity and was sequenced.

The N-terminal sequence of the 22,000 dalton band yielded an amino acid sequence described herein. A mature human IL-1 $\beta$  pro cDNA or an active fragment thereof was cloned using this N-terminal amino acid sequence and a three-stage polymerase chain reaction (PCR) procedure. In the first stage PCR procedure, fully degenerate PCR primers were designed and made from the N-terminal amino acid sequence. The degenerate primers were used to amplify IL-1 $\beta$  pro-specific sequences from a cDNA library prepared from THP-1 cell

mRNA. A random primed first strand THP-1 cDNA was constructed according to supplier instructions (Amersham). A mixed oligonucleotide primed amplification was carried out according to the proc dur described in Lee et al. "cDNA Cloning Using Degenerate Primers" in PCR Prot cols (Innis, Gelfand, Sninsky and White eds.) Academic Press, Inc. New York pp. 46-53 5 1990. Primer #1 was designed to cross-hybridize to IL-1 $\beta$  pro DNA (nucleotides 1-17) and to contain an Eco RI restriction site. Primer #1 had the sequence:  
10 5'-GTCAATTCAA(T/C)CCNGCNATGCCNAC-3'

(Seq. I.D. No. 9).

15 Primer #2 was designed to cross-hybridize to IL-1 $\beta$  pro DNA (complementary to nucleotides 31-47 and contain an Xba I restriction site. Primer #2 had the sequence:

5'-GTCTCTAGAAG(T/C)TTNAC(A/G)TTNCC(T/C)TC-3'

(Seq. I.D. No. 10).

20 PCR amplification was performed with thermus aquaticus polymerase (Perkin-Elmer Cetus) in 100  $\mu$ l of buffer for 30 cycles as described in Lee et al., infra. A 63 bp amplified fragment was obtained from PCR 25 amplification. This amplified fragment was subcloned into a pGem-4 vector (Promega). DNA sequence analysis of 10 isolates indicated that this fragment encoded the first 16 amino acids of the N-terminus of IL-1 $\beta$  pro as determined by purification and N-terminal sequence analysis.

---

30 The second stage of the PCR procedure made Primer #3 composed of nucleotides 1-17 (Figure 1) and a Not I restriction site and Primer #4 containing 20 T residues and a Not I restriction site. Primers #3 and #4 were added to the THP-1 cDNA library described above and PCR amplified for 6 cycles at 94°C for 1 minute, 35 50°C for 1 minute and 72°C for 1 minute. Southern

analysis of the PCR amplified clone using a 17 base  
1 lig nucle tide probe (complementary to nucleotides 16-  
32 in Figure 1) found a band at approximately 1000 bp  
that was also found to posses IL-1 $\beta$  pro biological  
5 activity. The 1000 bp DNA was gel purified, subjected  
to a similar second round of PCR and subcloned into  
pGem-5 for sequencing. The nucleotide sequence of this  
clone is shown in Figure 1.

In the third stage of PCR cloning, full length  
10 IL-1 $\beta$  pro clones were isolated from a cDNA library  
prepared from peripheral blood neutrophils. We found  
that neutrophils expressed IL-1 $\beta$  pro mRNA. We isolated  
two clones (p48 and p214) with IL-1 $\beta$  pro specific  
15 inserts of 1367 and 1360 base pairs, respectively. The  
DNA sequence shown in Figure 1 is a composite of all the  
IL-1 $\beta$  pro clones. The amino acids encoded by all of the  
IL-1 $\beta$  pro clones we found were identical.

IL-1 $\beta$  pro cDNA is approximately 1373 base  
20 pairs in length, including a stretch of A nucleotides  
corresponding to the poly (A) tail of mRNA. These A  
residues are preceded by two polyadenylation signals,  
AATAAA, at 1316 and 1335 base pair. The sequence has an  
open reading frame of 404 amino acids, starting with an  
initiator Met codon at nucleotide 18 and ending with a  
25 termination codon at nucleotide 1230. Initiation of  
translation could also begin with an in-frame Met codon  
at nucleotide 66. Both initiator Met codons have  
consensus Kozak translation initiation sequences.  
Polypeptides initiated with the Met residue at position  
30 51 also have biological activity.

IL-1 $\beta$  pro is a cytoplasmic enzyme. As the  
purified enzyme N-terminal amino acid is Asn (120), the  
protease undergoes N-terminal processing resulting in  
35 removal of 119 amino acids or 69 amino acids if the  
alternate initiator codon is used. Deletion analysis

has indicated that at least 107 amino acids are from the C-terminus. However, it appears that the full C-terminus is necessary for proper folding of the protein tease before approximately 107 C-terminal amino acids can be removed to insure biological activity for the protein tease.

5

The DNA sequence shown in Figure 1 was expressed in a mammalian cell (e.g., COS-7 cells). For mammalian cell expression, synthetic oligonucleotide primers were made to amplify the entire coding domain of IL-1 $\beta$  pro. The 5' primer

10

(5'-ATATCGGTACCGCCTCCAGCATGCCTCCGGCAATGCCACATC-3')

(Seq. I.D. No. 11)

15

contained an Asp 718 restriction site and an initiator Met residue fused to the N-terminus of the enzyme (nucleotides 1-20).

20

The 3' primer

(5'-CTGCTAGATCTGCCCGCAGACATTACAG-3')

(Seq. I.D. No. 12)

25

contains a Bgl II restriction site and is complementary to nucleotides 883-902 of Figure 1. The PCR generated fragment was ligated into pDC303 mammalian vector, as described in Mosley et al., Cell, 59:335-348 (1989).

30

Human IL-1 $\beta$  pro is preferably produced by recombinant DNA techniques. A recombinant DNA expression system inserts a clone encoding human IL-1 $\beta$  pro polypeptide or a derivative thereof with biological activity into an expression vector. The expression vector is inserted into a host cell. The host cell's protein synthesizing machinery synthesizes the recombinant human IL-1 $\beta$  pro polypeptide.

35

Suitable host cells for expression of mammalian IL-1 $\beta$  pro polypeptides or derivatives thereof include prokaryotes, yeast or higher eukaryotic cells

under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example E. coli or bacilli. Suitable prokaryotic hosts cells for transformation include, for example, E. coli, 5 Bacillus subtilis, Salmonella typhimurium, and various other species within the genera Pseudomonas, Streptomyces, and Staphylococcus. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could 10 also be employed to produce mammalian IL-1 $\beta$  pro polypeptides or derivatives thereof using RNAs derived from the DNA constructs disclosed herein. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are 15 described, for example, in Pouwels et al., Cloning Vectors: A Laboratory Manual, Elsevier, New York, (1985).

When an IL-1 $\beta$  pro polypeptide or derivative thereof is expressed in a yeast host cell, the 20 nucleotide sequence (e.g., structural gene) that codes on expression for an IL-1 $\beta$  pro polypeptide or derivative thereof may include a leader sequence. The leader sequence enables improved extracellular secretion of translated polypeptide by a yeast host cell.

25 Alternatively, in a prokaryotic host cell, such as E. coli, the IL-1 $\beta$  pro polypeptide or derivative thereof may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host cell. The N-terminal Met may be 30 cleaved from the expressed recombinant IL-1 $\beta$  pro polypeptide or derivative thereof. Moreover, prokaryotic host cells may be used for expression and disulfide processing.

35 The recombinant expression vectors carrying the recombinant IL-1 $\beta$  pro structural gene nucleotide

sequence or derivative thereof are transfected or transformed into a substantially homogeneous culture of a suitable host microorganism or mammalian cell line. Examples of suitable host cells include bacteria such as *E. coli*, yeast such as *S. cerevisiae*, or a mammalian cell line such as Chinese Hamster Ovary (CHO) cells.

Transformed host cells are cells which have been transformed or transfected with IL-1 $\beta$  pro or a derivative thereof structural gene nucleotide sequences. Expressed IL-1 $\beta$  pro polypeptides will be located within the host cell and/or secreted into culture supernatant, depending upon the nature of the host cell and the gene construct inserted into the host cell. Expression vectors transfected into prokaryotic host cells generally comprise one or more phenotypic selectable markers. A phenotypic selectable marker is, for example, a gene encoding proteins that confer antibiotic resistance or that supply an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host.

Other useful expression vectors for prokaryotic host cells include a selectable marker of bacterial origin derived from commercially available plasmids. This selectable marker can comprise genetic elements of the cloning vector pBR322 (ATTC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. The pBR322 "backbone" sections are combined with an appropriate promoter and an IL-1 $\beta$  pro structural gene sequence. Other commercially vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

Promoter sequences are commonly used for recombinant prokaryotic host cell expression vectors.

Common promoters include  $\beta$ -lactamase (penicillinase), lactose promoter system (Chang et al., Nature, 275:615, 1978; and Goeddel et al., Nature, 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res., 8:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p.412, 1982). A particularly useful prokaryotic host cell expression system employs a phage  $P_l$  promoter and a 10  $cI875ts$  thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the  $P_l$  promoter include plasmid pHUB2 (resident in E. coli strain JMB9 (ATCC 37092)) and pPLc28 (resident in E. coli RR1 (ATCC 53082)).

15 Human IL-1 $\beta$  pro polypeptides and derivative polypeptides may be expressed in yeast host cells, preferably from the Saccharomyces genus (e.g., S. cerevisiae). Other genera of yeast, such as Pichia or 20 Kluyveromyces, may also be employed. Yeast vectors will often contain an origin of replication sequence from a 2 $\mu$  yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, and sequences for transcription termination.

25 Preferably, yeast vectors include an origin of replication sequence and selectable marker. Suitable promoter sequences for yeast vectors include promoters for metallothionein, 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073, (1980)] or other 30 glycolytic enzymes [Hess, et al., J. Adv. Enzyme Res., 7:149, (1968); and Holland et al., Biochem. 17:4900, (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3- 35 phosphoglycerate mutase, pyruvate kinase,

triosephosphate isomerase, phosphoglucose isomerase, and glucose kinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EP-A-73,657.

Yeast vectors can be assembled, for example, using DNA sequences from pBR322 for selection and replication in *E. coli* (Amp<sup>r</sup> gene and origin of replication). Other yeast DNA sequences that can be included in a yeast expression construct include a glucose-repressible ADH2 promoter and  $\alpha$ -factor secretion leader. The ADH2 promoter has been described by Russell et al., [J. Biol. Chem., 258:2674, (1982)] and Beier et al., [Nature, 300:724, (1982)]. The yeast  $\alpha$ -factor leader sequence directs secretion of heterologous polypeptides. The  $\alpha$ -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. [See, e.g., Kurjan et al., Cell, 30:933, (1982); and Bitter et al., Proc. Natl. Acad. Sci. USA, 81:5330, (1984).] A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA, 75:1929, (1978). The Hinnen et al., protocol selects for Trp<sup>r</sup> transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 $\mu$ g/ml adenine and 20  $\mu$ g/ml uracil.

Yeast host cells transformed by vectors containing ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80  $\mu$ g/ml

adenine and 80  $\mu$ g/ml muacil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

5 Mammalian or insect host cell culture systems could also be employed to express recombinant IL-1 $\beta$  pro polypeptide or derivatives thereof. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells [Gluzman, Cell, 23:175, (1981)], L cells, C127 cells, 3T3 cells, Chinese hamster 10 ovary (CHO) cells, HeLa cells, and BHK cell lines. Suitable mammalian expression vectors include nontranscribed elements such as an origin of replication, a promoter sequence, an enhancer linked to the structural gene, other 5' or 3' flanking 15 nontranscribed sequences, such as ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.

20 Transcriptional and translational control sequences in mammalian host cell expression vectors may be provided by viral sources. For example, commonly used mammalian cell promoter sequences and enhancer sequences are derived from Polyoma, Adenovirus 2, Simian 25 Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful 30 because both are easily obtained from a viral genome as a fragment which may also contain a viral origin of replication [Fiers et al., Nature, 273:113, (1978)]. Smaller or larger SV40 fragments may also be used, providing the approximately 250 bp sequence extending

from the Hind III site toward the BglI site toward the SV40 viral origin of replication site is included.

5 Further, mammalian genomic IL-1 $\beta$  pro promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Exemplary vectors can be constructed as disclosed by Okayama and Berg [Mol. Cell. Biol., 3:280, (1983)].

10 Purified human IL-1 $\beta$  pro polypeptides or derivatives thereof are prepared by culturing transformed host cells under culture conditions necessary to express IL-1 $\beta$  pro polypeptides or derivatives thereof. The expressed polypeptides are purified from culture media or cell extracts. For example, supernatants from cultured transformed host 15 cells can secrete recombinant IL-1 $\beta$  pro polypeptide into culture media. The IL-1 $\beta$  pro polypeptide or derivative thereof is concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the 20 concentration step, the concentrate can be applied to a purification matrix. For example, a suitable purification matrix is an IL-1 $\beta$  pro inhibitor or an antibody molecule specific for an IL-1 $\beta$  pro polypeptide or derivative thereof and bound to a suitable support. Alternatively, an anion exchange resin can be employed, 25 for example, a matrix or substrate having pendent diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. 30 Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be 5 employed to further purify an IL-1 $\beta$  pro polypeptide composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein. Alternatively, some or all of the steps used in the 10 purification procedure described herein can also be employed.

Recombinant polypeptide produced in bacterial culture is usually isolated by initial disruption of the host cells, extraction from cell pellets of an insoluble 15 polypeptide, or from the supernatant of a soluble polypeptide, followed by one or more concentration, salting-out, ion exchange or size exclusion chromatography steps. Finally, reverse phase high performance liquid chromatography (RP-HPLC) can be 20 employed for final purification steps. Microbial cells can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Transformed yeast host cells generally express 25 IL-1 $\beta$  pro polypeptide as a secreted polypeptide. This simplifies purification. Secreted recombinant polypeptide from a yeast host cell fermentation can be purified by methods analogous to those disclosed by Urdal et al., [J. Chromatog., 296:171, (1984)]. Urdal et al., describe two sequential, reversed-phase HPLC 30 steps for purification of recombinant human IL-2 on a preparative HPLC column.

## II. Interleukin 1 $\beta$ Protease Inhibitors

Isolation and characterization of the protease responsible for processing precursor IL-1 $\beta$  into its biologically active form aids in designing inhibitors for IL-1 $\beta$  processing, because the availability of large quantities of IL-1 $\beta$  pro serves as a useful screening vehicle for finding compounds having IL-1 antagonist activity. Such IL-1 antagonists or IL-1 $\beta$  pro inhibitors are useful for treating inflammation and transplantation rejection.

The inhibitors of the present invention are substituted compounds comprising an amino acid sequence of from 1 to about 5 amino acid residues having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, which sequence represents the sequence of residues 112 to 116 of preIL-1 $\beta$ .

The amino acid sequence of preIL-1 $\beta$  is presented in Seq. I.D. No. 3 and in Figure 2 taken from March, C.J. et al., Nature (London), 315(6021):641-647 (1985). Mature IL-1 $\beta$  is represented by the C-terminal 153 amino acid residues of preIL-1 $\beta$ . Thus, the N-terminal of IL-1 $\beta$  is the Ala residue at position 117 of Seq. I.D. No. 3.

Amino acid residues can be expressed by the full name (e.g., alanine) or by the three letter designation (e.g., Ala). This application will use the three letter designation.

The naturally occurring amino acids are the L isomers and are so indicated without any isomeric (e.g., L or D) designation. The D isomers are so indicated.

As used herein, the phrase "corresponds to" means that a particular sequence of an inhibitor compound may differ from the disclosed sequence by one

r more conservative substitutions so long as such substitutions do not materially alter the inhibitory activity of the compounds of the present invention.

Examples of substitutions that do not materially alter inhibitory activity are replacement of the Ala at position 112 of Seq. I.D. No. 3 with Ser or Gly; replacement of the Tyr at position 113 of Seq. I.D. No. 3 with Phe; replacement of the Val at position 114 of Seq. I.D. No. 3 with Leu, Ile or Met and replacement of the His at position 115 of Seq. I.D. No. 3 with Phe, Pro, a positively charged amino acid such as Lys, Arg, His or Tyr, or the use of D isomers.

The C-terminal amino acid residue of the inhibitor compounds of the present invention is aspartic acid (Asp). Asp has a side chain of the formula  $\text{CH}_2\text{-COOH}$ . Preferably, the Asp side chain carboxyl group is protected to facilitate synthesis of the compounds of the present invention.

Asp side chain protection groups include, for example, a benzyl, substituted benzyl, formyl methyl or t-butyl moiety. The benzyl substituents increase the acid lability of the Asp side chain protecting moiety. Exemplary substituted benzyls are 2,4,6-trimethyl benzyl and 4-methoxybenzyl.

In a preferred embodiment, the Asp side chain protecting moiety is connected to the Asp side chain via an ester linkage, which linkage is subject to cleavage by naturally occurring intracellular esterase enzymes. In this way, the protected Asp with high lipid solubility gains access to a cell and is cleaved by an esterase to yield a charged, water soluble deprotected Asp that remains in the cytoplasm where IL-1 $\beta$  pro is predominantly located.

As used herein, the phrase "N-terminal blocking group" refers to chemical groups attached to

the amino group of the N-terminal amino acid residue of the sequences of the present invention. Such blocking groups are well known and readily apparent to those of skill in the art. The Peptides, ed. by Gross and Meienhofer, Academic Press, New York, pp. 3-81 (1981). N-terminal blocking groups have been utilized with other types of protease inhibitors. See, e.g., U.S. Patent Nos. 4,652,552 and 4,636,492.

As used herein, the phrase "electronegative leaving group" refers to chemical groups susceptible to nucleophilic attack by an amino acid residue in the enzyme active site, thus modifying IL-1 $\beta$  pro such that IL-1 $\beta$  pro cannot interact with and cleave preIL-1 $\beta$ .

The compounds of the present invention inhibit the catalytic activity of IL-1 $\beta$  pro in a reversible or an irreversible fashion. As used herein, "irreversible" means the formation of a covalent bond between the enzyme and the inhibitor.

The reversibility of IL-1 $\beta$  pro activity is a function of the electronegative leaving group. When the electronegative leaving group is a diazoalkyl ketone, the inhibition of IL-1 $\beta$  pro is irreversible and the compound is an irreversible inhibitor. When the electronegative leaving group is an aldehyde, the inhibition of IL-1 $\beta$  pro is reversible and the compound is a reversible inhibitor.

The compounds of the present invention have the formula:



where Z is an N-terminal blocking group; Q<sub>2</sub> is 0 to about 4 amino acids such that the sequence Q<sub>2</sub>-Asp corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and Q<sub>1</sub> is an electronegative leaving group.

In a preferred embodiment, Z is C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, acetyl, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl, benzyloxycarbonyl or C<sub>1</sub>-C<sub>6</sub> alkyl carbonyl. As used herein, "alkyl" refers to linear or branched chains having 1 to 6 carbon atoms, which may be optionally substituted as herein defined. Representative alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and the like. In a more preferred embodiment, Z is t-butoxycarbonyl (t-Boc), acetyl or benzyloxycarbonyl (Cbz).

Q<sub>2</sub> is preferably 1 amino acid. Preferably Q<sub>2</sub> is His, Phe, Pro, or Tyr. Most preferably, Q<sub>2</sub> is His or Phe.

Q<sub>1</sub> is preferably an aldehyde, a diazoalkyl ketone or a haloalkyl ketone. As used herein in reference to electronegative leaving groups, "alkyl" refers to linear or branched chain radicals having 1 to 3 carbon atoms, which may be optionally substituted as herein defined. Representative alkyl groups include methyl, ethyl, propyl and the like. More preferably, Q<sub>1</sub> is an aldehyde or fluoromethyl (CH<sub>2</sub>F) ketone.

The compounds of the present invention are made by techniques generally corresponding to methods known and readily apparent to those of skill in the art. See, e.g., Kettner, C.A. et al., Arch. Biochem. Biophys., 162:56 (1974); U.S. Patent No. 4,582,821; U.S. Patent No. 4,644,055; Kettner, C.A. et al., Arch. Biochem. Biophys., 165:739 (1974); Dakin, H.D. and West, R., J. Biol. Chem., 78:91 (1928); Rasnick, D., Anal. Biochem., 149:461 (1985).

Compounds having a fluoromethyl electronegative leaving group are preferably synthesized by the Rasnick procedure.

Compounds having a non-fluoro, haloalkyl ketone electronegative leaving group are synthesized in accordance with the Kettner procedure. An N-blocked

5 amino acid or peptide is reacted with N-methyl  
and an alkyl, non-fluoro haloformate to generate a  
peptide-acid anhydride. The anhydride is then reacted  
with a diazoalkane in an inert, aprotic solvent to  
form a peptide-diazomethane ketone. The diazomethane  
ketone is then reacted with an anhydrous salt in f  
HCl, HBr or HI to produce the desired N-blocked,  
C-terminal haloalkyl ketone peptide or amino acid.

10 Compounds having a fluoroalkyl ketone  
electronegative leaving group are synthesized in  
accordance with a Rasnick procedure. An N-blocked  
peptide is reacted with fluoroacetic anhydride and a  
trialkylamine in an organic solvent to form a peptide-  
anhydride. The anhydride is then reacted with a  
15 catalyst such as 4-dimethylaminopyridine and the  
reaction mixture maintained at about 25°C for about two  
hours to allow for CO<sub>2</sub> evolution. The reaction mixture  
is then extracted with an organic solvent and the  
organic phase washed and dried. The organic solvent is  
20 removed to form an oil, which is then applied to a  
silica gel column. The N-blocked, fluoroalkyl ketone  
peptide is then eluted from the gel and purified.

25 Compounds having a fluoroalkyl ketone  
electronegative leaving group can be extended in the N-  
terminus direction by removing the N-terminal blocking  
group and coupling the deprotected compound with other  
protected amino acids. Bodanszky, *The Practice of  
Peptide Synthesis*, Springer-Verlag, Berlin (1984).  
30 Alternatively, deprotected compounds are acetylated to  
yield compounds having an N-terminal acetyl protecting  
group. Stewart et al., *Solid Phase Peptide Synthesis*,  
Pierce Chemical Co., Rockford, IL. (1984).

35 III. Methods of Treatment and Pharmaceutical  
Compositions

The present invention provides methods of using therapeutic compositions comprising an effective amount of IL-1 $\beta$  pro polypeptides and derivatives thereof in a suitable diluent and carrier. For therapeutic use, 5 purified IL-1 $\beta$  pro or a biologically active derivative thereof is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, IL-1 $\beta$  pro compositions administered to suppress autoimmunity can be given by 10 bolus injection, continuous infusion, sustained release from implants, or other suitable technique. Typically, an IL-1 $\beta$  pro therapeutic agent will be administered in the form of a pharmaceutical composition comprising purified polypeptide in conjunction with physiologically 15 acceptable carriers, excipients or diluents. Such carriers will be nontoxic to patients at the dosages and concentrations employed and can contain any of the conventional excipients utilized to prepare pharmaceutically acceptable compositions.

20 The inhibitor compounds of the present invention are useful in inhibiting the physiological actions of interleukin 1 $\beta$  by preventing formation of biologically active IL-1 $\beta$ . The inhibition of IL-1 $\beta$  pro results in a decrease in active IL-1 $\beta$  levels and a 25 concomitant increase in preIL-1 $\beta$ , which compound is biologically inactive.

30 The inhibitor compounds of the present invention are also useful in treating dysfunctional states, such as autoimmune disease-associated inflammation, often mediated by increased IL-1 activity.

35 Mammals needing treatment for an inflammatory disorder or prevention of an autoimmune condition are administered effective amounts of the inhibitor compounds of this invention either alone or in the form of a pharmaceutical composition.

The pharmaceutical compositions of the present invention include one or more of the compounds of this invention formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection, for oral administration or solid or liquid form, for rectal or topical administration, and the like.

The total daily dose of the inhibitor compounds of this invention administered to a host in single or divided doses may be in amounts, for example, of from about 0.1 mg to about 160.0 mg per kilogram of body weight. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

The following examples are for the purposes of illustration and not by way of limitation.

25

#### EXAMPLES

EXAMPLE 1: Substrate specificity of IL-1 $\beta$  pro

This example illustrates the range of substrate specificity of purified human IL-1 $\beta$  pro enzyme to cleave a group of amino acid sequences. A variety of peptide substrates were prepared featuring changes in individual amino acids in the region corresponding to the cleavage site in human precursor IL-1 $\beta$  (His 115 to Pro 118). The reactivity of the peptide substrates was

expressed relative to the peptide corresponding to Ala 112 to Ser 121 of the precursor IL-1 $\beta$  sequence.

Substrate peptides were synthesized by solid phase method [Merrifield, J. Amer. Chem. Soc., 86:304-05 (1964)] using either an Applied Biosystems 430A peptide synthesizer or by the manual T-bag approach of Houghten [Proc. Nat. Acad. Sci. USA, 82:5131-35 (1985)]. 4-Methyl benzhydrylamine resin was used. The substrate peptides were acetylated prior to cleavage from resin, by liquid HF (0°C, 1 hr) in the presence of anisole as scavenger (HF:anisole 9:1). After evaporation of HF, the substrate peptide resin mixtures were washed with diethyl ether and extracted with 15% (w/v) acetic acid, lyophilized and purified on reverse phase high performance liquid chromatography (RP-HPLC) on a Vydac C18, 2.2cm x 25 cm column. Trifluoroacetic acid (0.1%) in water was solvent A and 0.1% trifluoroacetic acid in acetonitrile was solvent B for the mobile phases.

The purified substrate peptides were characterized by amino acid analysis using a Beckman 6300 system, RP-HPLC and mass spectrometry. Mass spectra were obtained by either fast atom bombardment on a VG Trio-2 system with xenon as the ionizing gas and glycerol/thioglycerol (1:1) as the sample matrix or by <sup>252</sup>Cf plasma desorption mass spectrometry on a Bio-Ion 20 mass spectrometer (See Tsarbopoulos, Peptide Res. 2:258-66 1989). In each case, the mass of the observed peptide substrate corresponded with the theoretical value.

Peptide solutions of standard concentration were prepared by dissolving about 2-3 mg of peptide substrate in water, loading the solution onto a Waters

5 Sep-Pak C18 cartridge and washing three times with 5 ml  
f water. The peptide substrates were eluted with  
acetonitrile and then evaporated to dryness. Each  
substrate was standardized to 1 mM by amino acid  
analysis prior to use.

10 Purified human IL-1 $\beta$  pro enzyme (10 $\mu$ l),  
peptide substrate in water (10 $\mu$ l), and 10 mM Tris  
buffer, pH 8.0 containing 25% v/v glycerol (10 $\mu$ l) were  
mixed and the mixtures were incubated at 37°C for four  
15 hours. The reaction was quenched with by adding 1 M  
glycine/HCl buffer pH 2.0 (10 $\mu$ l). The samples were then  
analyzed using RP-HPLC with a Vydac C18 column (0.46 cm  
x 25 cm) and eluting with a linear gradient from 100%  
solvent A to 70% solvent A/30% solvent B over 30 minutes  
20 at a flow rate of 1 ml/min. The effluent was monitored  
at 280 nm absorbing product. A comparison of peak area  
of product peptide to that of total peak area of  
substrate and product yielded the extent of peptide  
25 cleavage, because the area under the combined substrate  
and product peaks was constant and independent of the  
amount of cleavage by the IL-1 $\beta$  pro enzyme. Identities  
of peptide product peaks were confirmed by amino acid  
analysis and by mass spectrometry.

Table 1 shows the relative reactivities of a  
25 series of eight peptide substrates that were subject to  
digestion by purified IL-1 $\beta$  pro enzyme.

TABLE 1

	<u>Peptide</u>	<u>Sequence</u>	Reactivity R late To Peptide 1
5	1	Ala-Tyr-Val-His- Asp-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 13)	1.00
10	2	Ala-Tyr-Val-His- Asn-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 14)	<0.01
15	3	Ala-Tyr-Val-His- Glu-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 15)	<0.05
20	4	Ala-Tyr-Val-His- (D-Asp)-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 16)	<0.01
25	5	Ala-Tyr-Val-His- Asp-Gly-Pro-Val-Arg-Ser (Seq. I.D. No. 17)	3.40
30	6	Ala-Tyr-Val-His- Asp-Val-Pro-Val-Arg-Ser (Seq. I.D. No. 18)	<0.05
35	7	Ala-Tyr-Val-Phe- Asp-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 19)	0.50
	8	Ala-Tyr-Val-His- Asp-Ala-Ala-Val-Arg-Ser (Seq. I.D. No. 20)	0.47

The cleavage site can be described with the corresponding human precursor IL-1 $\beta$  amino acid residues as follows:

40 P2 P1 P1'P2'  
His-Asp-Ala-Pro

45 Changing the L-aspartic acid residue of peptide 1 to either asparagine (peptide 2), glutamic acid (peptide 3) or D-aspartate (peptide 4) has a profound effect on the ability of IL-1 $\beta$  pro to cleave the substrate. These data establish the requirement of an L-aspartate residue

in the P1 position for this enzyme to be able to cleave a substrate.

Peptides 5 and 6 represent changes in the P1' position of the human precursor IL-1 $\beta$  cleavage site. Replacing alanine with glycine (peptide 5) results in a substrate that is 3.4 times more reactive than peptide 1. However, changing the same residue to a valine (peptide 6) effectively prevents proteolytic cleavage. The fact that with a glycine residue in P1' the peptide is cleaved more readily suggests that the alanine residue in human precursor IL-1 $\beta$  polypeptide is not critical for substrate binding, while the result with a valine residue in the P1' position indicates low steric tolerance at the P1' position. Thus, it seems unlikely that the IL-1 $\beta$  pro enzyme or derivatives thereof will cleave anywhere other than between Asp-Gly and Asp-Ala residues.

Peptides 7 and 8 represent changes to the P2 and P2' sites, respectively. Changing the proline of peptide 1 to an alanine yielded a substrate which was still cleaved by human IL-1 $\beta$  pro but only half as efficiently as the peptide with human IL-1 $\beta$  native sequence. A similar result was obtained when the histidine of peptide 1 was replaced with a phenylalanine. These data suggest that human IL-1 $\beta$  pro enzyme tolerates conservative replacements of both residues and that the P2 and P2' positions are not as vital for activity as the amino acids at the P1 and P1' positions.

30

EXAMPLE 2: Effect of Substrate Length

This example illustrates the effect of substrate peptide length on the ability of human IL-1 $\beta$  pro enzyme to cleave peptide substrates. The experiment was conducted as described in Example 1. Five substrate

35

peptides were made that correspond to the amino acid sequence of the IL-1 $\beta$  pro cleavage site of human precursor IL-1 $\beta$ . The results are shown in Table 2 below:

5

Table 2

	<u>Peptide</u>	<u>Sequence</u>	<u>Reactivity Relative To Peptide 1</u>
10	1	Ala-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-Ser- (Seq. I.D. No. 13)	1.00
15	9	Glu-Ala-Tyr-Val-His-Asp-Ala-Pro- (Seq. I.D. No. 21)	0.74
20	10	Tyr-Val-His-Asp-Ala-Pro-Val-Arg- (Seq. I.D. No. 22)	2.40
25	11	Val-His-Asp-Ala-Pro-Val- (Seq. I.D. No. 23)	Not cleaved
30	12	His-Asp-Ala-Pro- (Seq. I.D. No. 24)	Not cleaved

30

The eight amino acid peptide (Ac-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-NH<sub>2</sub>) is cleaved most efficiently while the four and six amino acid peptides are not cleaved. Thus, IL-1 $\beta$  pro has a minimum number of amino acid residues necessary for substrate peptide cleavage.

**Example 3: Synthesis of IL-1 $\beta$  Protease Inhibitors**

**A. Synthesis of Boc-Asp-CH<sub>2</sub>F.**

A suspension of Boc-Asp-OH (8.11 mmol) and fluoroacetic anhydride (16.2 mmol) in benzene (30 ml) was treated with triethylamine (16.2 mmol) at room temperature. The catalyst 4-dimethylaminopyridine (0.41 mmol) was added to the solution and the reaction stirred

for about 2 h at room temperature. About 100 ml benzene was added to the reaction mixture. The organic solution was washed with 1N HCl (2 x 50 ml), saturated NaHCO<sub>3</sub> (2 x 50 ml), and saturated NaCl (2 x 50 ml), followed by drying over anhydrous MgSO<sub>4</sub>. The solvent was then removed by evaporation under reduced pressure. The resulting oil was applied to a 2.5 x 80 cm column of silica gel (60-200 mesh). The title compound was eluted with 2% methanol in chloroform.

10

B. Synthesis of Boc-His-Asp-CH<sub>2</sub>F, Boc-Tyr-Asp-CH<sub>2</sub>F and Boc-Phe-Asp-CH<sub>2</sub>F.

Boc-Asp-CH<sub>2</sub>F prepared in accordance with the method of Example 3A above may be dissolved in trifluoroacetic acid (TFA) and the mixture stirred for about 5 minutes at about 23°C. Cold ether may then be added to the mixture. The ether is evaporated and toluene added to co-evaporate residual TFA. The deprotected peptide (H-Asp-CH<sub>2</sub>F) is obtained as a TFA salt. The deprotected peptide may then be coupled to a protected amino acid (i.e., Boc-HisOH, Boc-ProOH, Boc-TyroOH, Boc-PheOH) using a standard symmetric anhydride procedure employing dicyclohexylcarbodiimide as a coupling reagent. Bodanszky, supra.

25

C. Synthesis of Ac-His-Asp-CH<sub>2</sub>F, Ac-Pro-Asp-CH<sub>2</sub>F, Ac-Tyr-Asp-CH<sub>2</sub>F and Ac-Phe-Asp-CH<sub>2</sub>F.

The Boc protecting groups may be removed from the compounds made in accordance with the method of Example 3B using trifluoroacetic acid as described above. Each deprotected compound may then be acetylated with acetic anhydride and diisopropylamine (DIAE) according to standard techniques. Stuart et al., supra.

D. Synthesis of Cbz-His-Asp-CH<sub>2</sub>F, Cbz-Pro-Asp-CH<sub>2</sub>F, Cbz-Tyr-Asp-CH<sub>2</sub>F and Cbz-Phe-Asp-CH<sub>2</sub>F.

The Boc protecting group may be removed from Boc-Asp-CH<sub>2</sub>F prepared according to the method of Example 5 3A using TFA as described above. Benzyloxycarbonyl-protected amino acids (i.e., Cbz-His-OH, Cbz-Phe-OH, Cbz-Tyr-OH, Cbz-Pro-OH) available from commercial sources (Bachem, Philadelphia, PA) can then be coupled to the deprotected Asp using a symmetric anhydride 10 coupling procedure. Bodanszky, supra.

**Example 4: Inhibition of IL-1 $\beta$  pro Activity**

Boc-Asp-CH<sub>2</sub>F was tested for its ability to inhibit IL-1 $\beta$  pro catalyzed degradation of preIL-1 $\beta$  15 using an in vitro assay method. Black, et al., J. Biol. Chem., 263(19): 9437 (1988). The results of this study are shown in Figure 3. Boc-Asp-CH<sub>2</sub>F was prepared in accordance with the method of example of 1A.

20

A. Production of preIL-1 $\beta$

Precursor preIL-1 $\beta$  polypeptide was obtained from E. coli using standard recombinant DNA techniques. Black, supra. Recombinant preIL-1 $\beta$  was expressed in E. coli under the control of the phage  $P_l$  promoter and CI857<sup>ts</sup> thermolabile repressor. Using standard 25 recombinant DNA techniques, pLNIL-1 $\beta$ F was constructed by ligating the following DNA segments: (1) 6160 base pairs of Nco I/Hind III-digested pLNIL-1 $\beta$  (12) containing the vector (conferring ampicillin resistance), codons 134- 30 269 and 3' noncoding regions of HuIL-1 $\beta$ ; (2) complementary synthetic oligonucleotides encoding residues 1-6 of IL-1 $\beta$  and Nco I and Sst I complementary ends; and (3) a 380-base pair Sst I/Hind III restriction fragment from plasmid IL-1 $\beta$ -6(1) encoding residues 7- 35 133. The ligation mixture was transformed into the

tetracycline-resistant host RRI:pRK248cl<sup>ts</sup> (12) and correctly assembled plasmids were identified by restriction analysis of DNA isolated from transformants resistant to both ampicillin and tetracycline.

5      Transformants containing pLNIL-1 $\beta$ F were tested for the production of preIL-1 $\beta$  by SDS-PAGE analysis of cultures grown in super induction medium to  $A_{600}$  of 0.5 and derepressed for 1-20 h by elevation of temperature from 30° to 42°C. A protein of about 31,000 daltons was

10     apparent in samples from pLNIL-1 $\beta$ F containing cultures but not in control cultures lacking the IL-1 $\beta$  coding region. Immuno-dot blot analysis with an anti-IL-1 $\beta$  monoclonal antibody (MAb) and purified recombinant mature IL-1 $\beta$  as a standard indicated that the cultures

15     contained approximately 2.5-5.0  $\mu$ g/ml of preIL-1 $\beta$ .

B. Extraction of preIL-1 $\beta$  from E. coli

Cell pellets from 2.5 liters of transferred E. coli culture were resuspended in 20 ml of 30mM Tris-HCl buffer (pH 9.5) containing 5mM ethylenediaminetetraacetic acid (EDTA), 500  $\mu$ g/ml of lysozyme, and 1mM phenylmethanesulfonyl (PMSF). The cell suspensions were homogenized using a Polytron homogenizer (Brinkmann Instruments), rapidly frozen in a Dry Ice/methanol bath, and then thawed. Next, 200 ml of 30 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 1 mM PMSF was added to the suspensions, which were then homogenized until a uniform homogenate was obtained. The suspensions were incubated for 30 minutes at 4°C, then centrifuged at 4°C for 60 minutes at 3800 X g. The supernatant fractions were carefully decanted and filtered to remove any particular matter. The pellets were re-extracted in 200 ml of 30mM Tris-HCl buffer (pH 8.0), containing 150 mM NaCl, 8 M urea, and 1 mM PMSF. Since both the Tris and the urea extracts contained

substantial amounts of the preIL-1 $\beta$ , both were purified as described below.

5                   C. Purification of preIL-1 $\beta$

10                 All chromatographic procedures were carried out at 4°C. All fractions were assayed for protein concentration, and conductivity was measured where appropriate. After each chromatographic step, fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE (with a 10-20% gradient of polyacrylamide), followed by silver staining, and by 15                 Western blot using a MAB generated against purified mature IL-1 $\beta$ .

20                 The extracts were diluted 1:4 in H<sub>2</sub>O, the pH was adjusted to 8.1, and the material was loaded at 100 ml/h onto a 25 X 2.5 cm Q-Sepharose column. For the Tris extract, the column was equilibrated in 10 mM Tris-HCl (pH 8.1). For the urea extract, the column was 25                 equilibrated in 10 mM Tris-HCl (pH 8.1), 2 M urea. The columns were washed with 8 column volumes of 10 mM Tris-HCl (pH 8.1), and the bound proteins eluted with a linear gradient (three column volumes) ranging from 0 to 1.5 M NaCl in 10 mM Tris-HCl (pH 8.1). Fractions of 7.5 ml were collected and stored at 4°C until the next step 25                 of the purification.

30                 The Q-Sepharose fractions containing the preIL-1 $\beta$  (as determined by Western blot analysis) were pooled and diluted 1:10 in 10mM Tris-HCl (pH 8.1). The column was washed with 4 column volumes of the starting buffer.

35                 The Tris-HCl solution was applied to a 20 X 5 cm column of phenyl-Sepharose CL-4B that had been equilibrated in 10 mM Tris HCl buffer (pH 8.1) containing 0.2 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. The column was washed with 3 column volumes of the starting buffer and then material

5 was eluted initially with 4 column volumes of a decreasing linear gradient of  $(\text{NH}_4)_2\text{SO}_4$ , generated with 0.2 and 0 M sucrose in 10 mM Tris-HCl buffer (pH 8.1). Finally, the material was eluted with 2 column volumes of 10 mM Tris-HCl (pH 8.1). Fractions containing partially purified preIL-1 $\beta$  were pooled, dialyzed against PBS, and stored at -70°C until use.

10 D. Proteolytic Treatment of preIL-1 $\beta$

15 5  $\mu\text{l}$  of preIL-1 $\beta$  (about 50  $\mu\text{g}/\text{ml}$  in PBS) was mixed with 10  $\mu\text{l}$  of purified IL-1 $\beta$  pro (15-75  $\mu\text{g}/\text{ml}$  in PBS) and incubated at 37°C for 30 minutes. The incubation was terminated by placing the samples on Dry Ice or by the addition of SDS sample buffer. PMSF was then added to a concentration of 1 mM, and the samples were dialyzed against water. After dialysis, the samples were concentrated to dryness in a Speed-Vac concentrator and dissolved in SDS sample buffer.

20 E. Western Blot Analysis of Proteolytic Products

25 SDS-PAGE was carried out with 12% polyacrylamide gels. The gels were placed in transfer buffer (0.192 M glycine, 0.025 M Tris-HCl (pH 8.3), 20% v/v methanol), and protein was then electrophoresed onto nitrocellulose (Sartorius) in a Hoeffer transfer apparatus (1 h at maximum voltage). The nitrocellulose was subsequently placed in 20 mM sodium phosphate, pH 7.4 (PBS) containing 3% bovine serum albumin for at least 15 minutes at room temperature. We used a MAb specific for mature IL-1 $\beta$  to probe the blot. MAb was added to a concentration of 9  $\mu\text{g}/\text{ml}$ , and the incubation was continued for 30 minutes. The blot was then rinsed three times with PBS and was developed with a solution

obtained by mixing 6 mg of horseradish peroxidase developing reagent (Bio-Rad) dissolved in 2 ml methanol and hydrogen peroxide (60  $\mu$ l diluted into 10 ml of Tris-buffered saline).

5 The data show that Boc-Asp-Ch<sub>2</sub>F completely inhibits the generation of mature IL-1 $\beta$  from preIL-1 $\beta$  at a concentration of 5  $\mu$ M and partially inhibits generation of mature IL-1 $\beta$  at a concentration of 1  $\mu$ M.

10 Example 5: Biological activity of IL-1 $\beta$  pro when transfected into COS-7 cells.

We inserted a cDNA corresponding to amino acids 120 to 404 into a mammalian cell expression vector (pDC303). This plasmid was co-transfected into COS-7 cells (monkey kidney) with a second mammalian expression plasmid containing a cDNA encoding precursor IL-1 $\beta$ . After two days, cells were radiolabeled with <sup>35</sup>S and IL-1 $\beta$  specific proteins were immunoprecipitated from cell lysates. The immunoprecipitates were analyzed by SDS-PAGE and autoradiography. We found that transfected COS-7 cells can process precursor IL-1 $\beta$  to mature IL-1 $\beta$  only if the cells were co-transfected with a plasmid encoding IL-1 $\beta$  pro. Cells co-transfected with a control plasmid or cells mock transfected did not show any processing of precursor IL-1 $\beta$ . Thus, IL-1 $\beta$  pro, lacking the N-terminal 119 amino acids enables cells to process precursor IL-1 $\beta$  to the mature form of this protein.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: BLACK, ROY A  
SLEATH, PAUL R  
KRONHEIM, SHIRLEY R

(ii) TITLE OF INVENTION: INTERLEUKIN 1B PROTEASE AND INTERLEUKIN 1B PROTEASE INHIBITORS

(iii) NUMBER OF SEQUENCES: 24

(iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: DRESSLER, GOLDSMITH, SHORE, SUTKER & MILNAMOW  
(B) STREET: 180 N. STETSON  
(C) CITY: CHICAGO  
(D) STATE: IL  
(E) COUNTRY: USA  
(F) ZIP: 60601

(v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.24

(vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: KATZ, MARTIN L.  
(B) REGISTRATION NUMBER: 25011  
(C) REFERENCE/DOCKET NUMBER: IMMUNEX2108

(ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: 3126165400  
(B) TELEFAX: 3126165460  
(C) TELEX: 9102211206

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 1659 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAAGGAGAG	AAAAGCCTAA	AAGAGAGTGG	GTAGATGGCC	GACAAGGTCC	TGAAGGAGAA	60
GAGAAAGCTG	TTTATCCGTT	CCATGGGTGA	AGGTACAATA	AATGGCTTAA	GGTAGAAGGT	120
GAAGGAAATA	CTGGATGAAT	TATTACAGAC	AAGGGTGCTG	AACAAGGAAG	AGATGGAGAA	180
AGTAAAACGT	GAAAATGCTA	CAGTTTATAG	AAAAGAAGAA	CGCTTATGGA	TAAGACCCGA	240
GCTTGATTG	ACTCCGTTAT	TCCGAAAGGG	GCACAGGCAT	GCCAAATTTG	CATCACATAC	300
CGGATAAGTG	AAAGTGATAA	TTTGTGAAGA	AGACAGTTAC	CTGGCAGGGA	CGCTGGGACT	360
CTCAGCAGAT	CAAACATCTG	GAAATTACCT	TAATTGAGGA	AAGAAAGAAA	ATTATGCAAG	420
ACTCTCAAGG	AGTACTTTCT	TCCTTCCAG	CTCCTCAGGC	AGTGCAGGAC	AACCCAGCTA	480
TGCCACAGG	GAACGGAAGA	GTGAATCCTC	AGGCTCAGAA	GGGAATGTCA	AGCTTGCTC	540
CCTAGAAGAA	GCTCAAAGGA	TATGGAAACA	AAAGTCGGCA	GTAAAGTAGA	ACAGGAGAGA	600
TTTATCCAAT	AATGGACAAG	TCAAGCCGCA	CACGTCTTGC	TCTCATTATC	TGCAATGAAG	660
AATTGACAG	TAGAGTGAAG	AATGTTGAG	TAATTCCCTAG	AAGAACTGGA	GCTGAGGTTG	720
ACATCACAGG	CATGACAATG	CTGCTACAAA	ATCTGGGTA	CAGCGTAAAA	TAATTTGGA	780
AAAAGGGATG	TGAAAAAAA	TCTCACTGCT	TCGGACATGA	CTACAGAGCT	GGAGGCATT	840
GCACACCGCC	CAGAGCACAA	GTATATGAGG	GCAGGACCTCT	GACAGCACGT	TCCTGGTGT	900
CATGTCTCAT	GGTATTGGG	AAGGCATTG	TGGGAAGAAA	CACTCTGAGG	AAGAAAATAT	960
ACACAAGTCC	CAGATATACT	ACAACCTAAC	GCAATCTTA	ACATGTTGAA	TACCAAGAAC	1020
TGCCCAAGTT	TGAAGGACAG	AACAGGAGAA	TAAGAAACCG	AAGGTGATCA	TCATCCAGGC	1080
CTGCCGTGGT	GACAGCCCTG	GTGTGGTGTG	GTTAAAGAT	TCAGTAGGAA	GATTGGAAA	1140
AAAGGTTCT	GGAAACCTAT	CTTACCAAC	TACAGAAGAG	TTTGAGGATG	ATGCTATTAA	1200
GAAAGCCCAC	ATAGAGAAGA	AACTAAATAG	TTGAGATTT	ATCGCTTCT	GCTCTCCAC	1260
ACCAAGATAAT	GTTCTTGGA	GACATCCCAC	AATGGGCTCT	GTTTTATTG	AGGTGGTAAC	1320
CAAGGAGAAG	GGAAGACTCA	TTGAACATAT	GCAAGAATAT	GCCTGTTCT	GTGATGTGGA	1380
GGAAATTTTC	CGCAAGGTTTC	GATTTGGAGA	GAAGTTGAG	ATTAGCTCA	TTTGAGCAGC	1440
CAGATGGTAG	AGCGCAGATG	CCCACCACTG	AAAGAGTGAC	TTTGACAAGA	TGTTTCTACC	1500

TCGTTCCCAG GACATTAAGGAAACT GTATGAATGT CTGCGGGCAG GAAGTGAAGA 1560  
 GATCGTTCTG TAAAAGGTTT TTGGAATTAT GTCTGCTGAA TAATAAACTT TTTTGAAAT 1620  
 AATAAATCTG GTAGAAAAAT GAAAAAAA AAAA 1659

## (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 404 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe Ile Arg Ser 15  
 1 5 10 15  
 Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Gln Thr 30  
 20 25 30  
 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 45  
 35 40 45  
 Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser Val Ile Pro Lys 60  
 50 55 60  
 Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp 80  
 65 70 75 80  
 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gln Thr Ser Gly 95  
 85 90 95  
 Asn Tyr Leu Asn Met Gln Asp Ser Gln Gly Val Leu Ser Ser Phe Pro 110  
 100 105 110  
 Ala Pro Gln Ala Val Gln Asp Asn Pro Ala Met Pro Thr Ser Ser Gly 125  
 115 120 125  
 Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala Gln Arg Ile 140  
 130 135 140  
 Trp Lys Gln Lys Ser Ala Glu Ile Tyr Pro Ile Met Asp Lys Ser Ser 160  
 145 150 155 160  
 Arg Thr Arg Leu Ala Leu Ile Ile Cys Asn Glu Glu Phe Asp Ser Ile 175  
 165 170 175

49

Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Thr Gly Met Thr Met Leu  
180 185 190

Leu Gln Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala  
195 200 205

Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His  
210 215 220

Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly Ile Arg  
225 230 235 240

Glu Gly Ile Cys Gly Lys Lys His Ser Glu Gln Val Pro Asp Ile Leu  
245 250 255

Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser  
260 265 270

Leu Lys Asp Lys Pro Lys Val Ile Ile Ile Gln Ala Cys Arg Gly Asp  
275 280 285

Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn  
290 295 300

Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala Ile Lys Lys  
305 310 315 320

Ala His Ile Glu Lys Asp Phe Ile Ala Phe Cys Ser Ser Thr Pro Asp  
325 330 335

Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe Ile Gly Arg  
340 345 350

Leu Ile Glu His Met Gln Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu  
355 360 365

Ile Phe Arg Lys Val Arg Phe Ser Phe Glu Gln Pro Asp Gly Arg Ala  
370 375 380

Gln Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu  
385 390 395 400

Phe Pro Gly His

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 269 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Ala Glu Val Pro Glu Leu Ala Ser Glu Met Met Ala Tyr Tyr Ser  
 1 5 10 15  
 Gly Asn Glu Asp Asp Leu Phe Phe Glu Ala Asp Gly Pro Lys Gln Met  
 20 25 30  
 Lys Cys Ser Phe Gln Asp Leu Asp Leu Cys Pro Leu Asp Gly Gly Ile  
 35 40 45  
 Gln Leu Arg Ile Ser Asp His His Tyr Ser Lys Gly Phe Arg Gln Ala  
 50 55 60  
 Ala Ser Val Val Val Ala Met Asp Lys Leu Arg Lys Met Leu Val Pro  
 65 70 75 80  
 Cys Pro Gln Thr Phe Gln Glu Asn Asp Leu Ser Thr Phe Phe Pro Phe  
 85 90 95  
 Ile Phe Glu Glu Glu Pro Ile Phe Phe Asp Thr Trp Asp Asn Glu Ala  
 100 105 110  
 Tyr Val His Asp Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp  
 115 120 125  
 Ser Gln Gln Lys Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala  
 130 135 140  
 Leu His Leu Gln Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met  
 145 150 155 160  
 Ser Phe Val Gln Gly Glu Glu Ser Asn Asp Lys Ile Pro Val Ala Leu  
 165 170 175  
 Gly Leu Lys Glu Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp  
 180 185 190  
 Lys Pro Thr Leu Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys  
 195 200 205  
 Lys Lys Met Glu Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn  
 210 215 220  
 Lys Leu Glu Phe Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr  
 225 230 235 240  
 Ser Gln Ala Glu Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly  
 245 250 255

51

Gln Asp Ile Thr Asp Phe Thr Met Gln Phe Val Ser Ser  
260 265

(2) INFORMATION FOR SEQ ID NO:4:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TACCGGCTGT TCCAGGAC 18

(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TACCTATTCT GGGCTCGA 18

(2) INFORMATION FOR SEQ ID NO:6:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTGGTCGATA CGGGTGT 17

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CACCACACCA AATTCTCA 18

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

ATGGAGAAGG GTCCTGTA 18

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTCGAATTCA AYCCNGCNAT GCCNAC 26

---

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTCTCTAGAA GYTTCACRTT NCCYTC 26

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATATCGGTAC CGCCTCCAGC ATGCCTCCGG CAATGCCAC ATC 43

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CTGCTAGATC TGCCCGCAGA CATTCTACAC G 31

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Ala Tyr Val His Asp Ala Pro Val Arg Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Ala Tyr Val His Asn Ala Pro Val Arg Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ala Tyr Val His Glu Ala Pro Val Arg Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
(B) LOCATION: 4  
(C) IDENTIFICATION METHOD: Xaa = D-Asp

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Ala Tyr Val His Xaa Ala Pro Val Arg Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid

(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Ala Tyr Val His Asp Gly Pro Val Arg Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 18:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Ala Tyr Val His Asp Val Pro Val Arg Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 19:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Ala Tyr Val Phe Asp Ala Pro Val Arg Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO: 20:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Ala Tyr Val His Asp Ala Ala Val Arg Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Glu Ala Tyr Val His Asp Ala Pro Val Arg Ser Leu  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Tyr Val His Asp Ala Pro Val Arg  
1 5

## (2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Val His Asp Ala Pro Val  
1 5

## (2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

57

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

His Asp Ala Pro  
1

**WHAT IS CLAIMED IS:**

1. An isolated polypeptide having protease activity for a specific protease cleavage site, wherein the protease activity is specific for a substrate peptide having an amino acid sequence comprising:



wherein  $R_1$  and  $R_3$  are independently any D or L isomer amino acid,  $R_2$  is Ala or Gly, and wherein the specific protease cleavage site is between Asp and  $R_2$ .

2. An isolated IL-1 $\beta$  pro polypeptide having IL-1 $\beta$  pro activity and encoded by a DNA sequence comprising:

- a. a DNA insert selected from the group consisting of the nucleotide sequences in Seq. I.D. No. 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, and beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962,

- b. DNA sequences which detectably hybridize to one or more of the foregoing DNA inserts and which code or express a polypeptide displaying biological activity to proteolytically cleave human precursor IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues; and

- c. DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 $\beta$  pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

3. An isolated DNA sequence encoding a mammalian IL-1 $\beta$  pro enzyme.

4. The isolated DNA sequence of claim 3 wherein the DNA sequence comprises:

a. a DNA insert selected from the group consisting of the nucleotide sequences in Seq. I.D. No. 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962;

b. DNA sequences which detectably hybridize to one or more of the foregoing DNA inserts and which code or express a polypeptide displaying biological activity to proteolytically cleave human precursor IL-1 $\beta$  polypeptide at a cleavage site between the Asp 116 and Ala 117 residues; and

c. DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 $\beta$  pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

5. A recombinant expression vector comprising a DNA sequence according to claim 3.

6. A process for preparing a mammalian IL-1 $\beta$  pro enzyme or an analog or derivative thereof, comprising culturing a suitable host cell comprising a vector according to claim 5 under conditions promoting expression.

7. A method for improving wound healing at a wound site, treating arthritis, treating an autoimmune disease or treating the deleterious effects of radiation treatment comprising administering a pharmaceutical composition to the wound site comprising the isolated polypeptide of claim 1 in a suitable pharmaceutical carrier.

- 60 -

8. An antisense oligonucleotide comprising a sequence of at least 15 nucleotides complementary to a sequence of IL-1 $\beta$  pro cDNA, wherein said antisense oligonucleotide inhibits translation of IL-1 $\beta$  pro mRNA.

9. A compound comprising an amino acid sequence of from 1 to about 5 amino acid residues having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein said amino acid sequence substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

10. The compound according to claim 9 having the formula:



where Z is an N-terminal protecting group;  $Q_2$  is 0 to 4 amino acids such that the sequence  $Q_2\text{-Asp}$  substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and

$Q_1$  is an electronegative leaving group:

11. A pharmaceutical composition comprising a physiologically acceptable carrier and a compound of claim 10.

12. A method of inhibiting IL-1 $\beta$  protease activity in a mammal in need of such treatment comprising administering to said mammal an effective inhibitory amount of a compound of claim 10.

13. A method of treating inflammation or preventing and treating an autoimmune disease in a mammal in need of such treatment comprising

administering to said mammal an effective amount of a compound of claim 10.

14. A compound selected from the group consisting of Boc-Asp-CH<sub>2</sub>F, Boc-His-Asp-CH<sub>2</sub>F, Boc-Phe-Asp-CH<sub>2</sub>F, Boc-Pro-Asp-CH<sub>2</sub>F, Boc-Tyr-Asp-CH<sub>2</sub>F, Ac-His-Asp-CH<sub>2</sub>F, Ac-Phe-Asp-CH<sub>2</sub>F, Ac-Pro-Asp-CH<sub>2</sub>F, Ac-Tyr-Asp-CH<sub>2</sub>F, Cb<sub>3</sub>-His-Asp-CH<sub>2</sub>F, Cb<sub>3</sub>-Phe-Asp-CH<sub>2</sub>F, Cb<sub>3</sub>-Pro-Asp-CH<sub>2</sub>F, and Cb<sub>3</sub>-Tyr-Asp-CH<sub>2</sub>F wherein Boc is t-butoxycarbonyl, Ac is acetyl and Cb<sub>3</sub> is benzyloxycarbonyl.

AAAAGGAGAG	AAAGGCC	ATG	GGC	GAC	AGG	GTC	CTG	AAG	GAG	AAG	AGA	AAG	50				
Met	Ala	Asp	Lys	Val	Leu	Lys	Glu	Leu	Lys	Arg	Arg	Lys	10				
													98				
CTG	TTT	ATC	CGT	TCC	ATG	GGT	GAA	GGT	ACA	ATA	AAAT	GGC	TTA	CTG	GAT	15	
Leu	Phe	Ile	Arg	Ser	Met	Gly	Gl	Gly	Thr	Ile	Asn	Gly	Leu	Leu	Leu	Asp	20
																25	
GAA	TTA	TCA	CAG	ACA	AGG	GTG	CTG	AAC	AAG	GAA	GAG	ATG	GAG	AAA	GTA	146	
Glu	Leu	Leu	Gln	Thr	Arg	Val	Leu	Asn	Lys	Glu	Glu	Met	Glu	Lys	Val	30	
																35	
AAA	CGT	GAA	AAT	GCT	ACA	GTT	ATG	GAT	AAG	ACC	CGA	GCT	TTG	ATT	GAC	194	
Lys	Arg	Glu	Asn	Ala	Thr	Val	Met	Asp	Lys	Thr	Arg	Ala	Leu	Ile	Asp	45	
																50	
TCC	GTT	ATT	CCG	AAA	GGG	GCA	CAG	GCA	TGG	CAA	ATT	TGC	ATC	ACA	TAC	242	
Ser	Val	Ile	Pro	Lys	Gly	Ala	Gln	Ala	Cys	Gln	Ile	Cys	Ile	Thr	Tyr	60	
																65	
ATT	TGT	GAA	GAA	GAC	AGT	TAC	CTG	GCA	GGG	ACG	CTG	GGA	CTC	TCA	GCA	290	
Ile	Cys	Glu	Glu	Asp	Ser	Tyr	Leu	Ala	Gly	Thr	Leu	Gly	Leu	Ser	Ala	95	
																80	
GAT	CAA	ACA	TCT	GGA	AAT	TAC	CIT	AAT	ATG	CAA	GAC	TCT	CAA	CGA	GTA	338	
Asp	Gln	Thr	Ser	Gly	Asn	Tyr	Leu	Asn	Met	Gln	Asp	Ser	Gln	Gly	Val	100	
																105	

CTT TCT TCC TTT CCA CCT CAG GCA GTG CAG GAC AAC CCA GCT ATG  
 Leu Ser Ser Phe Pro Ala Pro Gln Ala Val Gln Asp Asn Pro Ala Met  
 110 115 120

CCC ACA TCC TCA GGC TCA GAA GGG AAT GTC AAG CTT TGC TCC CTA GAA  
 Pro Thr Ser Ser Gly Ser Gly Asn Val Lys Leu Cys Ser Leu Glu  
 125 130 135

GAA CCT CAA AGG ATA TGG AAA CAA AAG TCG GCA GAG ATT TAT CCA ATA  
 Glu Ala Gln Arg Ile Trp Lys Gln Lys Ser Ala Glu Ile Tyr Pro Ile  
 140 145 150 155

ATG GAC AAG TCA AGC CGC ACA CGT CCT GCT ATT ATC TGC AAT GAA  
 Met Asp Lys Ser Ser Arg Thr Arg Leu Ala Leu Ile Ile Cys Asn Glu  
 160 165 170

GAA TTT GAC AGT ATT CCT AGA AGA ACT GGA GCT GAG GTT GAC ATC ACA  
 Glu Phe Asp Ser Ile Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Thr  
 175 180 185

GGC ATG ACA ATG CTG CTA CAA AAT CTC GGG TAC AGC GTA GAT GTG AAA  
 Gly Met Thr Met Leu Leu Gln Asn Leu Gly Tyr Ser Val Asp Val Lys  
 190 195 200

AAA ATT CTC ACT GCT TCG GAC ATG ACT ACA GAG CTG GAG GCA TTT GCA  
 Lys Asn Leu Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala  
 205 210 215

FIG. 1B

CAC CGC CCA GAG CAC ACC TCT GAC AGC ACG TTC CTG GTG TTC ATG	722
His Arg Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met	225
TCT CAT GCT ATT CGG GAA GGC ATT TGT GGG AAG AAA CAC TCT GAG CAA	770
Ser His Gly Ile Arg Glu Gly Ile Cys Gly Lys Lys His Ser Glu Gln	240
GTC CCA GAT ATA CTA CAA CTC AAT GCA ATC TTT AAC ATG ATG TTT AAT ACC	818
Val Pro Asp Ile Leu Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Thr	255
AAG AAC TGC CCA AGT TTG AAG GAC AAA CCG AAG GTG ATC ATC ATC CAG	866
Lys Asn Cys Pro Ser Leu Lys Asp Lys Pro Lys Val Ile Ile Ile Gln	270
GCC TGC CGT GGT GAC AGC CCT GGT GTG TGG TTT AAA GAT TCA GTA	914
Ala Cys Arg Gly Asp Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val	285
GGA GTT TCT GGA AAC CTA TCT TTA CCA ACT ACA GAA GAG TTT GAG GAT	962
Gly Val Ser Gly Asn Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp	300
GAT GCT ATT AAG AAA GCC CAC ATA GAG AAG GAT TTT ATC GCT TTC TGC	1010
Asp Ala Ile Lys Lys Ala His Ile Glu Lys Asp Phe Ile Ala Phe Cys	325

FIG. IC

TCT TCC ACA CCA GAT AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT  
 Ser Ser Thr Pro Asn Val Ser Trp Arg His Pro Thr Met Gly Ser 1058  
 335 340 345

GTT TTT ATT GGA AGA CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC  
 Val Phe Ile GLY Arg Leu Ile Glu His Met Gln Glu Tyr Ala Cys Ser 1106  
 350 355 360

TGT GAT GTG GAG GAA ATT TTC CGC AAG GTT CGA TTT TCA TTT GAG CAG  
 Cys Asp Val Glu Glu Ile Phe Arg Lys Val Arg Phe Ser Phe Glu Gln 1154  
 365 370 375

CCA GAT GGT AGA GCG CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA  
 Pro Asp GLY Arg Ala Gln Met Pro Thr Thr Glu Arg Val Thr Leu Thr 1202  
 380 385 390 395

AGA TGT TTC TAC CTC TTC CCA GCA CAT TAAATAAGG AAACCTGTATG  
 Arg Cys Phe Tyr Leu Phe Pro Gly His 405 400

AATGTTCTGGCG GGCAGGAAGT GAAGAGATCG TTCTCTAAAGG GGTTTTGGAA ATTATGTCCTG 1309  
 CTGAATAATA AACTTTTTT GAAATAATAA ATCTCTGAGA AAAATGAAAAA AAAAAAAA 1369  
 AAAA 1373

Met Ala Glu Val Pro Glu Leu Ala Ser Glu Met Met Ala Tyr Tyr Ser  
10  
Gly Asn Glu Asp Asp Leu Phe Phe Glu Ala Asp Gly Pro Lys Gln Met  
20  
Lys Cys Ser Phe Gln Asp Leu Asp Leu Cys Pro Leu Asp Gly Gly Ile  
40  
Gln Leu Arg Ile Ser Asp His His Tyr Ser Lys Gly Phe Arg Gln Ala  
50  
Ala Ser Val Val Val Ala Met Asp Lys Leu Arg Lys Met Leu Val Pro  
70  
Cys Pro Gln Thr Phe Gln Glu Asn Asp Leu Ser Thr Phe Pro Phe  
90  
Ile Phe Glu Glu Pro Ile Phe Phe Asp Thr Trp Asp Asn Glu Ala  
100  
Tyr Val His Asp Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp  
120  
Ser Gln Gln Lys Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala  
130

6/7

Leu His Leu Gln Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met  
150 160

Ser Phe Val Gln Gly Glu Glu Ser Asn Asp Lys Ile Pro Val Ala Leu  
170

Gly Leu Lys Glu Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp  
180 190

Lys Pro Thr Leu Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys  
200

Lys Lys Met Glu Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn  
210 220

Lys Leu Glu Phe Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr  
230 240

Ser Gln Ala Glu Asn Met Pro Val Phe Leu Gly Thr Lys Gly Gly  
250

Gln Asp Ile Thr Asp Phe Thr Met Gln Phe Val Ser Ser  
260 269

FIG. 2B

PROTEASE + PRO-IL-1 $\beta$

+ INHIBITOR ( $\mu$ M)

PRO. 25 10 5 1 MAT.




FIG. 3

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/06595

## I. CLASSIFICATION & SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC  
 IPC(5): C07K 13/00, 15/00; A61K 37/02, 37/64; C12P 21/02; C12N 15/24; 15/70; C07H 15/12  
 U.S. CL.: 530/300, 350, 351; 536/27; 435/69.1, 69.2, 69.52, 172.3, 252.3, 262, 320.1; 424/85.1, 94.63

## II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
U.S.	530/350, 300, 351; 536/27, 26; 435/69.1, 69.2, 69.52, 172.3, 183, 219, 226, 240.1, 243, 252.3, 262, 320.1; 424/85.1, 85.2, 94.63, 94.65, 94.66, 930/240, 250, 141; 935/49, 51, 14

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched \*

A computer data-base search for IL-1 2/10 enzyme or protease; antisense and oligonucleotide; or peptide and inhibitor; Files 5,16,73,76,77,144, 155,350, 351, CA; Intelligent sequence search.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT \*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X Y	Journal of Biological Chemistry, Vol. 264, No. 10, issued 05 April 1989. Block et al.. "A Pre-Aspartate-Specific Protease for Human Leukocytes that Cleanses Pro-Interleukin-1 $\beta$ ". pages 5323-5326. see pages 5323-25.	1-2 3-14
X Y	FEBS. Vol. 247, No. 2, issued April 1989. Black et al.. "Activation of Interleukin-1 $\beta$ by a Co-Induced Protease". pages 386-390. see pages 386-89.	1-2 3-14
Y	Proc. Natl. Acad. Sci... Vol. 87, issued July 1990. Kobayastic et al.. "Identification of Calcium-Activated Neutral Protease as a Processing Enzyme of Human Interleukin 1 $\alpha$ ". pages 5548-5552. see all.	1-14

- \* Special categories of cited documents: 10
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

09 December 1991

Date of Mailing of this International Search Report

18 DEC 1991

International Searching Authority  
ISA/US

Signature of Authorized Officer  
Diane Proffete for  
Garnette D. Draper, Prim. Exam.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SEC ND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Proc. Natl. Acad. Sci.. vol. 85: issued September 1988, Seelmeier et al.. "Human Immunodeficiency Virus has an Aspartic-type Protease that can be Inhibited by Pepstatin A". pages 6612-6616. see pages 6612-6615.	1 7
X	Nature. Vol. 337. issued 16 February 1989. Blundell et al.. "A Second Front Against AIDS". pages 596-97, see all.	1 7
X	Lymphokine Research. Vol. 9. No. 1, issued 1990. Manson et al.. "Modulation of Interleukin 1 $\beta$ Gene Expression using Antisense Phosphorothioate Oligonucleotide". pages 35-42. see page 35.	8
X	Trends in Pharmacol. Sci., Vol. 10, No. 11. issued November 1989. Cohen. "Designing Antisense Oligonucleotide as Pharmaceutical Agents". pages 433-37, see all.	8
X	Barrett et al.. "Proteinase Inhibitors". published 1986. by Elsevier Science Publishers BV. pages 179-208. see pages 179-182. 189. 204-207.	9-14
X	Infection and Immunity. Vol. 58, No. 9, issued September 1990, Parmely et al.. "Proteolytic inactivation of Cytokines by <u>Pseudomonas aeruginosa</u> ", pages 3009-14.	1-14
X	Journal of Immunology. Vol. 140. No. 7. issued 01 April 1988. Kobayashi et al.. "Phosphorylation of Intracellular Precursors of Human IL-1", pages 2279-2287.	1-14
X	WO. A, 91/00912 (Ringe) 24 January 1991. See all.	1-14